PL2101791T3 - Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia - Google Patents

Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia

Info

Publication number
PL2101791T3
PL2101791T3 PL07853353T PL07853353T PL2101791T3 PL 2101791 T3 PL2101791 T3 PL 2101791T3 PL 07853353 T PL07853353 T PL 07853353T PL 07853353 T PL07853353 T PL 07853353T PL 2101791 T3 PL2101791 T3 PL 2101791T3
Authority
PL
Poland
Prior art keywords
wound healing
impaired wound
healing compositions
anticonnexin
polynucleotides
Prior art date
Application number
PL07853353T
Other languages
English (en)
Inventor
David L Becker
Colin R Green
Bradford J Duft
Original Assignee
Coda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics Inc filed Critical Coda Therapeutics Inc
Publication of PL2101791T3 publication Critical patent/PL2101791T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07853353T 2006-12-11 2007-12-11 Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia PL2101791T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87440406P 2006-12-11 2006-12-11
PCT/US2007/025446 WO2008073479A2 (en) 2006-12-11 2007-12-11 Anticonnexin polynucleotides as impaired wound healing compositions
EP20070853353 EP2101791B1 (en) 2006-12-11 2007-12-11 Anticonnexin polynucleotides as impaired wound healing compositions

Publications (1)

Publication Number Publication Date
PL2101791T3 true PL2101791T3 (pl) 2015-04-30

Family

ID=39386432

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07853353T PL2101791T3 (pl) 2006-12-11 2007-12-11 Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia

Country Status (15)

Country Link
US (5) US8063023B2 (pl)
EP (3) EP2543378A1 (pl)
JP (3) JP5431949B2 (pl)
KR (1) KR101521306B1 (pl)
CN (2) CN103520197B (pl)
AU (1) AU2007333535B2 (pl)
BR (1) BRPI0721094A2 (pl)
CA (1) CA2672220A1 (pl)
DK (1) DK2101791T3 (pl)
ES (1) ES2527131T3 (pl)
PL (1) PL2101791T3 (pl)
PT (1) PT2101791E (pl)
RU (1) RU2521329C2 (pl)
SI (1) SI2101791T1 (pl)
WO (1) WO2008073479A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
CN102920996A (zh) * 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物
AU2008335717A1 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
EP2237795A2 (en) * 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
WO2012076985A2 (en) * 2010-12-06 2012-06-14 The University Of British Columbia Granzyme b inhibitor compositions, methods and uses for promoting wound healing
GB201117538D0 (en) * 2011-10-11 2011-11-23 Royal Veterinary College The Methods
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
JP2015513905A (ja) * 2012-03-27 2015-05-18 コーダ セラピューティクス， インコーポレイテッド カドヘリン調節に基づく組成物および処置
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2941140A1 (en) * 2014-03-14 2015-09-17 Coda Therapeutics Treatment of resistant lesions
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
US10450569B2 (en) * 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
WO2018060144A1 (en) * 2016-09-27 2018-04-05 Smith & Nephew Plc Wound closure devices with dissolvable portions
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (pl) 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
EP0950060A4 (en) 1996-12-02 2000-07-05 Dyad Pharmaceutical Corp COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES
RU2147240C1 (ru) * 1998-02-16 2000-04-10 Рязанский областной клинический кожно-венерологический диспансер Препарат для лечения длительно незаживающих инфицированных язв и ран
US7098190B1 (en) * 1999-01-27 2006-08-29 Coda Therapeutics Ltd. Formulations comprising antisense nucleotides to connexins
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにｅｄｈｆ
CN1939529A (zh) 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
CN1922320B (zh) * 2003-12-03 2013-04-24 科达治疗（新西兰）有限公司 靶向连接蛋白的反义化合物及其使用方法
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
EP1827480B1 (en) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
CN101573131B (zh) * 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
AU2008335717A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
CN102920996A (zh) 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物

Also Published As

Publication number Publication date
CN103520197A (zh) 2014-01-22
JP5911454B2 (ja) 2016-04-27
JP2010512404A (ja) 2010-04-22
RU2009126594A (ru) 2011-01-20
US20120289579A1 (en) 2012-11-15
US8063023B2 (en) 2011-11-22
AU2007333535B2 (en) 2014-04-17
JP2015063565A (ja) 2015-04-09
JP2013173796A (ja) 2013-09-05
RU2521329C2 (ru) 2014-06-27
US8685940B2 (en) 2014-04-01
US20080242631A1 (en) 2008-10-02
CN101835476A (zh) 2010-09-15
EP2543377A1 (en) 2013-01-09
WO2008073479A2 (en) 2008-06-19
CN101835476B (zh) 2016-08-17
EP2101791A2 (en) 2009-09-23
US20130143952A1 (en) 2013-06-06
HK1136213A1 (en) 2010-06-25
WO2008073479A3 (en) 2008-08-07
BRPI0721094A2 (pt) 2014-02-11
US20170240905A1 (en) 2017-08-24
CN103520197B (zh) 2017-11-21
PT2101791E (pt) 2014-12-18
CA2672220A1 (en) 2008-06-19
EP2101791B1 (en) 2014-09-10
US9637745B2 (en) 2017-05-02
EP2543378A1 (en) 2013-01-09
JP5431949B2 (ja) 2014-03-05
US9029339B2 (en) 2015-05-12
DK2101791T3 (en) 2015-01-05
KR20090118910A (ko) 2009-11-18
KR101521306B1 (ko) 2015-05-18
SI2101791T1 (sl) 2015-02-27
US20150315598A1 (en) 2015-11-05
AU2007333535A1 (en) 2008-06-19
ES2527131T3 (es) 2015-01-20

Similar Documents

Publication Publication Date Title
SI2101791T1 (sl) Antikoneksin polinukleotidi kot spojine za slabĺ e celjenje ran
HUS2000015I1 (hu) Fungicid készítmények
ZA200900240B (en) Antibacterial compositions
GB0624290D0 (en) Novel compositions
EP2116224A4 (en) COSMETIC COMPOSITION
IL193359A0 (en) Ezetimibe compositions
GB0624340D0 (en) Antimicrobial composition
IL198651A0 (en) COMPOSITION COMPRISING (-)-Ôêå9-TRANS-TETRAHYDROCANNABIONOL
GB0621023D0 (en) Fragrance compositions
IL197235A0 (en) Therapeutic compositions
EP2059126A4 (en) ANTIMICROBIAL COMPOSITION CONTAINING ISOTHIAZOLIN-3-ONE
GB0625069D0 (en) Compositions
GB0607085D0 (en) Novel compositions
IL195074A0 (en) Imidazoazepinone compounds
GB0601644D0 (en) Antiperspirant compositions
GB0620279D0 (en) Compositions
GB0621020D0 (en) Fragrance compositions
GB0618657D0 (en) Compositions
ZA200901574B (en) Topical compositions
GB0619375D0 (en) Wound healing compositions
GB0620918D0 (en) Compositions
GB0622847D0 (en) Cosmetic composition
GB0601899D0 (en) Compositions
GB0917779D0 (en) Novel compositions
GB0611033D0 (en) Compositions